Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 29

Results For "EIR"

3460 News Found

JP Nadda highlights preventive healthcare push on World Health Day
Policy | April 08, 2026

JP Nadda highlights preventive healthcare push on World Health Day

Union Health Minister says India’s healthcare model blends traditional wisdom with modern science, backed by Ayushman Bharat and Janaushadhi expansion


Asia emerges new hotspot for healthcare ransomware, says report
Digitisation | April 08, 2026

Asia emerges new hotspot for healthcare ransomware, says report

Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs


Trialt and Viedoc team up to transform clinical trials
Clinical Trials | April 08, 2026

Trialt and Viedoc team up to transform clinical trials

The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide


IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals
Digitisation | April 08, 2026

IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals

AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17


Transgene and NEC join forces to advance personalized cancer vaccine
R&D | April 08, 2026

Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor


Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion
News | April 08, 2026

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio


Biocon launches denosumab biosimilars Bosaya and Aukelso in US market
Biopharma | April 08, 2026

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market


Lupin wins USFDA nod for generic Dapagliflozin tablets
Drug Approval | April 08, 2026

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market